News | September 17, 2007

FDA Clears High-Definition Collimator for IMRS

September 18, 2007 – Varian Medical Systems has received FDA 510(k) clearance for a new high-definition multileaf collimator (MLC), the HD120 MLC, an ultra-fine beam shaping device for radiosurgery, optimized for targeting tumors and other abnormalities with high-dose stereotactic radiotherapy and radiosurgery.

The new HD120 MLC multileaf collimator enables clinicians to deliver extremely precise radiosurgical treatments, including intensity-modulated radiosurgery (IMRS), and will be included with the new Novalis Tx radiosurgery system that Varian is teaming up with BrainLab to offer.

The Novalis Tx offers a noninvasive alternative to conventional surgery for a wide spectrum of conditions, including benign and malignant tumors, metastatic cancer and neurological conditions like arteriovenous malformations, trigeminal neuralgia and acoustic schwannoma.

Varian’s new HD120 MLC multileaf collimator doubles the resolution of our best MLC, and is designed carrying out delicate intensity-modulated radiosurgeries near critical structures like the optic chiasm, brain stem or spinal cord.

The HD120 MLC has reduced the width of the central leaves from 5 millimeters wide to 2.5 millimeters, theoretically increasing the beam-shaping precision by 100 percent.

The new collimator also steeper dose fall-off gradient, so that the amount of dose delivered decreases rapidly outside the targeted area, protecting healthy tissues more effectively than is possible with earlier beam shaping devices.

For more information: www.varian.com

Related Content

Surgically Guided Brachytherapy Improves Outcomes for Intracranial Neoplasms
News | Brachytherapy Systems | April 18, 2019
Peter Nakaji, M.D., FAANS, general practice neurosurgeon at Barrow Neurological Institute, presented new research on...
ASTRO Applauds Introduction of PIMA Patient Protection Bill
News | Radiology Business | April 15, 2019
The American Society for Radiation Oncology (ASTRO) hailed the introduction of federal legislation that would...
Varian Discloses First Preclinical Results of Flash Therapy in Cancer Treatment
News | Proton Therapy | April 09, 2019
Varian, in partnership with the University of Maryland School of Medicine’s Department of Radiation Oncology and the...
Varian Halcyon Commissioned at MedStar Southern Maryland Hospital Center With IBA's myQA Halo
News | Quality Assurance (QA) | April 04, 2019
IBA (Ion Beam Applications S.A.) announced the successful commissioning of the Varian Halcyon at the Radiation Oncology...
Four of the top pieces of content in March included news on proton therapy, including a 360 image and videos from ITN's recent visit to the Northwestern Medicine Proton Center in the Chicago suburbs. This image shows the main proton treatment room gantry at the proton center in Warrenville, Ill. Interview with Mark Pankuch, Ph.D.

Four of the top pieces of content in March included news on proton therapy, including a 360 image and videos from ITN's recent visit to the Northwestern Medicine Proton Center in the Chicago suburbs. This image shows the main proton treatment room gantry at the proton center in Warrenville, Ill.
 

Feature | April 02, 2019 | Dave Fornell, Editor and A.J. Connell
April 2, 2019 — Here is the list of the most popular content on the Imaging Technology News (ITN) magazine w
ZON-PTC in Clinical Use With RayStation 8B and Hyperscan
News | Treatment Planning | March 19, 2019
Zuid-Oost Nederland Protonen Therapie Centrum (ZON-PTC), Maastricht, Netherlands, recently treated its first patient...
What to Expect from the Proton Therapy Market in 2019-2020
News | Proton Therapy | March 13, 2019
The number of new particle therapy rooms ordered worldwide dropped by almost 20 percent in 2018, according to a new...
Mississippi Cancer Center Combines RayStation and TomoTherapy for Prostate Cancer Case
News | Treatment Planning | March 08, 2019
Anderson Regional Cancer Center in Meridian, Miss., has treated its first patient using the combination of RaySearch's...
Videos | Proton Therapy | March 01, 2019
ITN Associate Editor Jeff Zagoudis speaks with Mark Pankuch, Ph.D., director of physics and dosimetry at the...